We examined combat-related open extremity fracture infections as a function of whether posttrauma antimicrobial prophylaxis included expanded Gram-negative (EGN) coverage.
A ntimicrobial prophylaxis and thorough debridement are important interventions in the prevention of infectious complications after combat-related traumatic injury. Although the use of prophylactic antibiotics active against Gram-positive organisms is uniformly recommended in all relevant posttrauma antimicrobial prophylaxis guidance, [1] [2] [3] [4] [5] 
the value of expanded
Gram-negative (EGN) coverage (e.g., addition of fluoroquinolones and/or aminoglycosides) is uncertain. In particular, two prominent guidelines have divergent recommendations about the role of EGN coverage in Type III open fractures for the prevention of skin and soft-tissue infections (SSTIs) and osteomyelitis. 1, 5 Because of these conflicting recommendations, the development of clear guidance for combat-related trauma proved to be challenging.
Clinical practice guidelines (CPGs) for the prevention and management of posttrauma infections are based on civilian trauma data 1, 2, [5] [6] [7] [8] [9] [10] where trauma commonly presents with different injury mechanisms (e.g., lower rate of blast injuries), reduced injury severity, and shorter route to tertiary-care hospital (as opposed to combat trauma care, which begins in combat zone and is followed by medical evacuation from theater to a regional hospital before transport to the United States). As a result, the Department of Defense (DoD) Joint Trauma System convened an expert consensus panel to develop guidelines for use in the military setting. The first CPG for the prevention of infections after combat-related trauma was published in 2008 and recommended using cefazolin or clindamycin for posttraumatic antibiotic prophylaxis with all open fractures. 11 In 2010, contrasting recommendations were included in a guidance document published by the Joint Trauma System (based on civilian guidelines), 5, 9 which advocated use of EGN coverage along with a Grampositive regimen when there were Type III open fractures and maxillofacial injuries. These contradictory recommendations were reconciled when a revised CPG (published in 2011) 12 and a corresponding Joint Trauma System guidance document (released in 2012) 13 both recommended against the addition of EGN coverage to posttrauma antibiotic prophylaxis for open fractures.
After circulation and publication of the revised CPG in 2011, antibiotic stewardship efforts focused on reducing the use of broad-spectrum antibiotic prophylaxis, along with decreasing the duration of prophylaxis. Specifically, the proportion of wounded military personnel with open fractures who received EGN coverage as part of posttraumatic antibiotic prophylaxis decreased from above 50% to less than 10% in 2013-2014. 14 This marked change in practice patterns allowed us to retrospectively evaluate infectious outcomes in patients with comparable injury severity who sustained open extremity fractures based on whether they did or did not receive EGN coverage (i.e., fluoroquinolones or aminoglycosides).
METHODS

Study Population and Data Collection
Trauma patients were eligible for inclusion in the analysis if they were DoD beneficiaries, 18 years of age or older, and sustained at least one deployment-related open extremity fracture in either Iraq or Afghanistan (June 1, 2009 to May 31, 2014) requiring medical evacuation to Landstuhl Regional Medical Center (Germany) before transitioning to a participating military hospital in the United States. The study population was restricted to patients who were hospitalized for at least 7 days in the United States. Data were collected from the time of injury until the patient was discharged from their initial trauma U.S. hospitalization as part of an observational cohort study, the Trauma Infectious Disease Outcomes Study (TIDOS), which was designed to assess the short-and long-term infectious complications related to deployment-related traumatic injuries. 15 This study was approved by the Infectious Disease Institutional Review Board of the Uniformed Services University of the Health Sciences (Bethesda, MD).
Patient data (e.g., age, sex, and military status) and injury characteristics (e.g., injury mechanism, specific traumatic injury pattern, and date/location of injury) were obtained from the DoD Trauma Registry, 16 whereas infection-related information was retrieved from the supplemental TIDOS infectious disease module. 15 Infections (SSTIs and osteomyelitis) were identified using clinical findings and laboratory test results by reviewing medical records and were classified based upon National Healthcare Safety Network (NHSN) standardized definitions (Table 1) . 15, 17 Infectious disease events were included if there was a clinical diagnosis associated with directed antimicrobial treatment (duration: ≥5 days for SSTIs and ≥21 days for osteomyelitis) even if the a priori definitions were not met. An infection was excluded from the analysis if an alternate diagnosis was recorded along with discontinuation of antimicrobial therapy. Multidrug-resistant organisms (MDROs) were identified based on NHSN definitions 18 and were collected as part of admission infection control-based surveillance swabs and clinical infection work-ups.
Injury Characterization and Classification
Information related to injury characteristics were obtained from the DoD Trauma Registry and standardized into Abbreviated Injury Scale-defined codes 19 using Tri-Code, an injury 
Antimicrobial Prophylaxis Classification
As previously described, 14, 20 antibiotic usage was determined through prospective medical record review. Antibiotic prophylaxis regimens were classified as narrow or EGN for the analysis. Narrow antibiotic prophylaxis was defined as any use of cefazolin or clindamycin. Because many patients transited coalition treatment facilities where IV amoxicillin-clavulanate was used as a substitute for cefazolin, this antibiotic (and ampicillinsulbactam) was also classified as narrow. Coverage was defined as EGN if the patient received a fluoroquinolone (e.g., levofloxacin) and/or aminoglycoside (e.g., gentamicin) in addition to narrow coverage. Patients who received macrolides, antifungals (prescribed because of concern for invasive fungal infections), oral antibiotics (with the exception of oral levofloxacin), and/or antibiotics traditionally used to target MDROs (e.g., carbapenems, piperacillin-tazobactam, and vancomycin) were excluded from the analysis. Patients were also excluded if they did not receive any antibiotics. Patients who received doxycycline for antimalarial prophylaxis (per DoD regulations) 21 were not excluded from the analysis. Antimicrobial prophylaxis was assessed in the period immediately after injury up to 48 hours (i.e., day of injury and day after the injury) to account for the potential of documentation omissions and multiple transitions of care associated with combat trauma care/medical evacuation. 20, 22 Antibiotics provided immediately after injury before admission to combat support hospitals were not included in the analysis.
Statistical Analysis
Primary endpoints were defined prospectively, including SSTI, osteomyelitis, isolation of MDROs, and Clostridium difficile infections. Resistance of Gram-negative organisms to fluoroquinolones and aminoglycosides was also assessed. Secondary endpoints included mortality, length of hospitalization, and trips to the operating room.
Categorical variables were compared using Fisher's exact and χ 2 tests. Kruskal-Wallis test was used to compare overall continuous variable distributions. Cox proportional hazard univariate and multivariate analyses were used to examine risk factors in time-to-infection models. Kaplan-Meier plots were used to examine time to first infection. Statistical analysis was performed with SAS version 9.3 (SAS, Cary, NC). Significance was defined as p <0.05.
RESULTS
Study Population
During the study period (June 2009 to May 2014), there were 2,564 patients with combat-related trauma transitioned through the medical evacuation pipeline to a participating U.S. hospital. Of these trauma patients, 419 had a hospitalization period less than 7 days and 791 did not have qualifying extremity trauma, so they were excluded. An additional 310 trauma patients were excluded based on their antibiotic prophylaxis regimen. As a result, 1,044 military personnel who sustained an open extremity fracture met the inclusion criteria for the analysis.
The 1,044 trauma patients were primarily male (99%) and injured in support of operations in Afghanistan (95%) via a blast mechanism (81%), resulting in severe injuries (Injury Severity Score [ISS] 23 median of 22; Table 2 ). The median duration of hospitalization for the study population was 33 days. Patients with only lower extremity open fractures were the majority EGN, expanded Gram-negative coverage; ICU, intensive care unit; IQR, interquartile range; LRMC, Landstuhl Regional Medical Center; OR, operating room; RBC, red blood cell.
*Expanded Gram-negative (i.e., addition of fluoroquinolone and/or aminoglycoside to narrow coverage). **Injury Severity Score is an overall measure calculated for each patient based on the top three maximum Abbreviated Injury Scale anatomical region values. 23 †p value is for the comparison of the Injury Severity Score profile between the regimen groups.
‡Duration is restricted to narrow-spectrum antibiotics: IV cefazolin, clindamycin, amoxicillin-clavulanate, and/or ampicillin-sulbactam.
(58%), whereas patients with open fractures of either both the upper and lower extremities or only upper extremities represented 24% and 19% of the study population, respectively. Injury codes based on general anatomic site for open fracture varied with "lower leg" (n = 608), "thigh" (n = 364), and "forearm" (n = 223) being predominant. When specific bones were identified, 36% of patients had a fracture of the tibia/fibula only, 13% with a femur fracture only, and 22% with a fracture of both tibia/fibula and femur.
A total of 585 (56%) patients received a narrow posttrauma antibiotic regimen, whereas 459 (44%) received EGN coverage ( p < 0.001). Patients who received EGN coverage had a larger proportion of blast injuries (84% vs. 79%; p = 0.025; Table 2 ); however, there was no significant difference in injury severity (median ISS: 22 for both groups) or units of blood transfused within 24 hours (median of 9 vs. 10). In addition, 427 (93%) and 554 (95%) patients in the EGN coverage and narrow regimen groups (p = 0.260), respectively, received doxycycline antimalarial prophylaxis.
Antimicrobial Use Patterns
Narrow prophylaxis was exclusively cefazolin (or clindamycin) for 74% of patients, whereas 26% received at least one dose of a beta-lactam beta-lactamase inhibitor (e.g., IV amoxicillinclavulanate). For patients with EGN coverage, 81% received a fluoroquinolone in addition to a narrow regimen, 10% received an aminoglycoside, and 9% received both a fluoroquinolone and aminoglycoside. Narrow-spectrum antibiotics were received by all but six patients in the EGN group. When a patient's regimen was classified as narrow, they had a significantly shorter duration of antibiotic use (median: 3 days; interquartile range: 2-6 days) compared to the use of narrow-spectrum antibiotics among patients in the EGN group (median: 6 days; interquartile range: 3-11 days; p < 0.001). Over the study period, the use of EGN prophylaxis significantly declined from 73% during 2009-2010 to 6% in 2013-2014 ( p < 0.001).
Non-Infection Outcomes
Between the patients who received EGN coverage and a narrow regimen, there was no significant difference in the number of operating room visits (median of 4 vs. 5, respectively) or duration of hospitalization (median of 32 vs. 34 days) ( Table 3 ). There was also no difference in mortality between the two groups, and the deaths that occurred were in very severely injured soldiers and not caused by SSTI or osteomyelitis.
Among patients who received EGN coverage, 49% had Gram-negative organisms isolated (from any site) that were not susceptible to fluoroquinolones and/or aminoglycosides compared to 40% among patients who received a narrow regimen ( p < 0.001; Table 3 ). When restricted to patients with Gramnegative organism recovery (311 patients with EGN coverage and 433 patient in the narrow regimen group), the proportion of organisms that were resistant to fluoroquinolones and/or aminoglycosides was 73% and 55%, respectively.
Infection Outcomes
A total of 262 patients developed SSTIs, of which 235 had SSTIs that were classified as deep (i.e., involves deep soft tissues, such as fascia and muscle layers of the wound), whereas 45 were categorized as superficial (i.e., involves only skin and subcutaneous tissue). Eighteen patients had both deep and superficial SSTIs. Among the 262 patients, 28% had a SSTI event involving the lower leg (e.g., tibia/fibula), 42% the thigh (e.g., femur), and 11% had infections with both the lower leg and thigh. The majority of extremity SSTI events fulfilled the NHSN diagnostic criteria (94%), whereas only a few (6%) qualified as an infection event based only on antibiotic use directed at the wound for greater than 5 days. Extremity SSTIs were more common in patients who received narrow prophylaxis (28% vs. 22%; p = 0.029; Table 3) .
Eighty-two patients developed osteomyelitis with the lower leg and thigh being the site of infection for 34% and 29% of patients, respectively. The proportion of osteomyelitis was comparable between regimen groups (8%). In addition, there was no significant difference in the isolation of a MDRO (colonizing and/or infecting isolates), methicillin-resistant Staphylococcus aureus, and vancomycin-resistant Enterococcus within the first 2 weeks of injury with narrow prophylaxis and EGN coverage. Furthermore, there was also no significant difference in the proportion of non-extremity infections and Clostridium difficile infections between the groups.
Time to first SSTI and osteomyelitis diagnosis was a median of 7 (interquartile range: 4-13 days) and 17 days (interquartile range: 8-28 days) postinjury, respectively. Time to infection was also analyzed after the removal of eight SSTI and six osteomyelitis outliers because their infection was diagnosed outside of 45 days from date of injury. Using this subset, patients who received a narrow regimen had a shorter duration after injury to development of SSTIs (Fig. 1, A) . When the SSTIs were restricted to deep SSTIs (data not shown), representing 90% of SSTI events, the results were similar. There was no statistical difference related to timing of osteomyelitis onset between the narrow and EGN treatment groups (Fig. 1, B) . In the unadjusted Cox proportional hazard model used to assess the association of prophylaxis and injury-related factors on the timing of infections after injury, receiving narrow prophylaxis was associated with an increased risk of any extremity wound infection (hazard ratio [ or antibiotic duration variables were associated with osteomyelitis risk. In the adjusted model (Table 4) , receipt of narrow prophylaxis remained independently associated with the risk of any extremity infection and SSTIs; however, there was no significant association with prophylaxis regimen and osteomyelitis risk. For any extremity infection and SSTIs, sustaining a blast injury and admission to the intensive care unit at a U.S. hospital were also significantly associated with infection risk. Severe injuries (ISS >15) and critical injuries (ISS ≥26) were also associated with risk of any extremity infection and SSTIs, respectively. Having a narrow-spectrum antibiotic duration of ≤6 and ≤3 days was also significantly associated with risk for any extremity wound infection and SSTI, respectively. There were no factors significantly associated with risk of osteomyelitis. Prophylaxis regimen, antibiotic duration, and injury variables were also assessed in a logistic regression model with similar results (data not shown).
Furthermore, a Cox proportional hazard analysis was performed with the same variables after excluding 305 patients (151 and 153 in the narrow regimen and EGN coverage groups, respectively) who received a beta-lactam beta-lactamase inhibitor medication. Similar to the overall study population, the use of a narrow regimen in open fractures slightly increased the risk of SSTI (HR: 1.80; 95% CI: 1.28-2.54), but did not increase the risk of osteomyelitis (HR: 1.33; 95% CI: 0.75-2.35). The analysis was also run on a smaller cohort restricted to patients with blast injuries (excluded 198 patients with non-blast injuries [125 and 73 in the narrow regimen and EGN coverage groups, respectively]). Similar to the other models, SSTI rates were lower with EGN coverage (HR: 1.46; 95% CI: 1.12-1.91), and there was no increased risk of osteomyelitis (HR: 0.94; CI: 0.58-1.51). Our results demonstrate that the addition of EGN coverage (in the form of a fluoroquinolone or aminoglycoside) to guideline-directed, narrow posttrauma prophylaxis decreased the risk of an extremity SSTI with open fractures. The absolute reduction in risk was approximately 6-7% (number needed to treat = 16.7) with the greatest amount of risk reduction accrued in the first 2-3 weeks after injury. There was no increased risk of osteomyelitis in the patients who received narrow coverage. These findings are consistent with the results of a recent study that examined 90 patients with open fractures of the lower extremities, of which 27 had Grade III fractures according to Gustilo Anderson classification. Among the patients with severe fractures, 59% were prescribed Gram-negative coverage in addition to cefazolin; however, there was no significant difference in the rate of osteomyelitis between the groups. 28 Based on the reduction of risk of SSTIs, one could argue that this study supports EGN prophylaxis in severe open fractures akin to those encountered in our combat veterans; however, a recommendation must consider the overall benefits and risks placed in the context of the patient setting. Although there was a small effect on SSTIs in our patient population, there was no difference in osteomyelitis rates. This is notable because osteomyelitis tends to affect limb length more than SSTI. Additionally, this cohort represents a high percentage of severely injured combat-trauma patients (particularly severe blast trauma) where SSTI is difficult to accurately diagnose because of the complicated wounds, frequently characterized by extensive soft-tissue and/or muscle loss. Approximately one-fourth to one-third of these patients still developed SSTI regardless of the prophylaxis choice. In our opinion, emphasis is more appropriately placed on thorough and meticulous debridement, timely use of narrow guideline-directed antibiotic prophylaxis, and early recognition and aggressive debridement and empiric broad-spectrum antibiotics when extremity infection is suspected.
DISCUSSION
Other than slightly decreasing the rate of SSTI, the use of EGN conveyed no other benefit and had adverse effects on 28% ; p = 0.286), suggesting there is a not surprising antibiotic resistance cost to using EGN prophylaxis. There are also other potential negative impacts of EGN prophylaxis (e.g., effect of aminoglycoside use on renal function and potential toxic effects of fluoroquinolones on bone remodeling); however, these were not examined in our analysis. Although we feel our study supports current recommendations, it is important to emphasize that the guidelines were developed to compliment the clinical judgment of the trauma team. It is also important to note that we excluded patients who received broad-spectrum antibiotics and antifungals, so our findings should not be applied to patients where empiric treatment for sepsis in the early days after trauma is being considered. Because of the high injury severity of our population, our results may also not be applicable to those with minimally injured open fractures.
Our primary limitation is that our analysis was not a randomized control trial, but a retrospective observational study involving a heterogeneous population. However, the clear change in the antibiotic prophylaxis practice patterns that occurred simultaneously with the roll-out period of the new CPG allowed us to study the two management approaches in a period where many of the other factors affecting infection risk (e.g., injury severity and injury mechanism), and our clinical definitions of SSTI and osteomyelitis, remained constant. One factor that our retrospective design does not control for is the possibility of varying approach to the diagnosis of osteomyelitis and SSTI by different clinicians, but it is unlikely that clinical criteria changed in a way that would alter our results. Of note, injury severity did decrease toward the end of the study period, with a corresponding reduction in blast injuries. Notwithstanding, the effects seen with SSTI (or lack of effect with osteomyelitis) and prophylaxis regimens did not change after adjusting for injury severity.
Another limitation of our dataset is that duration of antibiotic prophylaxis was longer than what current guidelines recommend. This finding concurs with previously published TIDOS analysis showing prophylaxis durations in excess of guideline recommendations.
14 Duration also varied between treatment groups with the EGN treatment group having a longer duration of use of narrow-spectrum antibiotics. However, although longer prophylaxis duration of narrow-spectrum antibiotics decreased SSTI risk, there was no effect on the risk of developing osteomyelitis with the use of longer prophylaxis durations.
Another limitation is that the open fracture classification was not fully defined. Nevertheless, fractures in this analysis were primarily the result of blast injuries (81%) and gunshot wounds (16%). Therefore, we feel this study population predominantly represents open Type III fractures that present with environmental contamination and is relevant to both combat and non-combat trauma that occurs under similar conditions.
In addition, antibiotic prophylaxis choice was based on the judgment of trauma providers, so regimens varied. For example, EGN coverage was more common in blast patients who tended to have higher injury severity and more environmental contamination. Yet, when the cohort was limited to only blast trauma patients, the findings were similar. Many patients also received amoxicillin-clavulanate (29% of the study population) with or without EGN when they were initially treated at a non-U.S. coalition hospital under coalition guidelines. 26, 27 Nonetheless, when these patients were removed from the analysis, the effect of EGN coverage on SSTIs and osteomyelitis did not differ from the total study population.
Information on antibiotics provided by first medical responders before admission to combat support hospitals is also lacking. A previous study demonstrated that 28% of combat casualties received one-time point-of-injury antimicrobials (which are not captured in the medical record and may include ertapenem or moxifloxacin), 29 so it is possible that a small number of patients who received antibiotics immediately after injury may have been included in the analysis. Our study did not capture who did and did not receive these point-of-injury antimicrobials because of a lack of documentation; however, we feel it is unlikely that the percentage of patients who received these antimicrobials would be different between the treatment groups. It is also unlikely they would have an impact on the development of SSTI or osteomyelitis in higher-risk individuals where blood product use in the first 24-48 hours often times significantly exceeds 10 U of blood.
In summary, our findings provide evidence to support the current post-combat trauma antibiotic prophylaxis guidelines directing antibiotic choices in open fractures. Importantly, neither the guidelines nor the findings of this study should deter clinicians from using their clinical judgment and individualizing care; however, the results of our retrospective analysis should reassure trauma providers that withholding EGN antibiotics from post-combat trauma antibiotic prophylaxis regimens for extremity injuries will not increase the risk of osteomyelitis. Given the high rates of extremity infections, with or without EGN coverage, clinicians should monitor wound sites closely and initiate treatment as soon as the diagnosis is considered likely.
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